The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents

Study identification

• EU PAS number:
  EUPAS48481
• Study ID:
  48491
• Official title and acronym:
  The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents
• DARWIN EU® study:
  No
• Study countries:
  Belgium
• Study description:
  Objectives: Angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor blockers (ARBs), and HMG-CoA reductase inhibitors (“statins”) have been hypothesized to affect COVID-19 severity. However, up to now, no studies investigating this association have been conducted in the most vulnerable and affected population groups (ie, older adults residing in nursing homes). The objective of this study was to explore the association of ACEi/ARB and/or statins with clinical manifestations in COVID-19einfected older adults residing in nursing homes. Design: We undertook a retrospective multicenter cohort study to analyze the association between ACEi/ ARB and/or statin use with clinical outcome of COVID-19. The outcomes were (1) serious COVID-19 defined as long-stay hospital admission or death within 14 days of disease onset, and (2) asymptomatic (ie, no disease symptoms in the whole study period while still being diagnosed by polymerase chain reaction). Setting and participants: A total of 154 COVID-19epositive subjects were identified, residing in 1 of 2 Belgian nursing homes that experienced similar COVID-19 outbreaks. Measures: Logistic regression models were applied with age, sex, functional status, diabetes, and hypertension as covariates. Results: We found a statistically significant association between statin intake and the absence of symptoms during COVID-19 (odds ratio OR 2.91, confidence interval CI 1.27e6.71), which remained statistically significant after adjusting for covariates (OR 2.65, CI 1.13e6.68). Although the effects of statin intake on serious clinical outcome were in the same beneficial direction, these were not statistically significant (OR 0.75, CI 0.24e1.87). There was also no statistically significant association between ACEi/ ARB and asymptomatic status (OR 2.72, CI 0.59e25.1) or serious clinical outcome (OR 0.48, CI 0.10e1.97).
• Study status:
  Finalised

Study timelines

Date when funding contract was signed

Planned:16/02/2020

Actual:16/02/2020

Study start date

Planned:01/03/2020

Actual:16/04/2020

Data analysis start date

Planned:16/04/2020

Date of final study report

Planned:31/05/2020

Actual:31/05/2020

Sources of funding

Other

More details on funding

Foundation Flanders (FWO) (grant number 1158818N)., Self-funded (university)

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

https://doi.org/10.1016/j.jamda.2020.06.018